Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 13/20 | 0.64 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380456 | 1.00 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL30513340 | 1.00 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL29433930 | 1.00 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31619566 | 0.97 | IL23R (0.61) | IL23R | |
| SCHEMBL30276251 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL30379397 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL38662290 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31619557 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31091578 | 0.97 | IL23R (0.66) | IL23RGHSR | |
| SCHEMBL29507073 | 0.97 | GHSR (0.60) | IL23RKISS1RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102526-A1 | 177LUTETIUM-DOTA-TATE FORMULATIONS | CURIUM US LLC | 2026-04-16 | — | — | US | disclosed |
| EP-4644406-A1 | RADIOLABELED MEDICINE | National University Corporation Chiba University (JP) | 2025-11-05 | — | — | EP | disclosed |
| EP-4637826-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025000035-A1 | METHODS FOR THE DIAGNOSIS AND/OR TREATMENT OF NEUROENDOCRINE CANCERS | Clarity Pharmaceuticals Limited (AU) | 2025-01-02 | — | — | WO | disclosed |
| US-20240350679-A1 | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE | CURIUM US LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-12102696-B2 | Radiolabeling and formulation for scale up of 64Cu-DOTATATE | Curium US, LLC (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240285816-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING | Clarity Pharmaceuticals Ltd (AU) | 2024-08-29 | — | — | US | disclosed |
| WO-2024143314-A1 | RADIOLABELED MEDICINE | 国立大学法人千葉大学 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024133780-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-117777235-A | Porphin modified polypeptide molecules and synthesis method thereof | 南京农业大学 | 2024-03-29 | — | — | CN | disclosed |
| JP-2023179429-A | CHELATING AAZTA CONJUGATES AND COMPLEXES THEREOF | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 2023-12-19 | — | — | JP | disclosed |
| CN-112996764-B | Chelate AAZTA conjugate and complex thereof | 伯拉考成像股份公司 | 2023-11-21 | — | — | CN | disclosed |
| US-11684682-B2 | Chelating AAZTA conjugates and complexes thereof | BRACCO IMAGING S.P.A. (IT) | 2023-06-27 | — | — | US | disclosed |
| EP-3880635-B1 | CHELATING AAZTA CONJUGATE, COMPLEXES THEREOF AND USE | BRACCO IMAGING SPA (IT) | 2023-01-04 | — | — | EP | disclosed |
| CN-115087467-A | Structurally optimized methods for improving the therapeutic diagnostic performance of peptide receptor targeted radionuclide therapy for cancer | 衣阿华大学研究基金会 | 2022-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684682-B2 | Chelating AAZTA conjugates and complexes thereof | SLC39A11, SLC30A5, SLC39A14 | IL23R 1100/4885KISS1R 1953/4885GHSR 3342/4885 |
| US-12102696-B2 | Radiolabeling and formulation for scale up of 64Cu-DOTATATE | SSTR1, SSTR5, SSTR4 | IL23R 1503/4885KISS1R 75/4885GHSR 35/4885 |
| US-20240350679-A1 | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE | SSTR1, SSTR5, SSTR4 | IL23R 1503/4885KISS1R 75/4885GHSR 35/4885 |
| US-20260102526-A1 | 177LUTETIUM-DOTA-TATE FORMULATIONS | TAAR1, SLC7A11, MCHR1 | IL23R 124/4885KISS1R 246/4885GHSR 73/4885 |
| US-20240285816-A1 | FORMULATIONS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING | XPO5, XPOT, TP53 | IL23R 1921/4885KISS1R 1070/4885GHSR 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.